EXPERIMENTAL STUDY

MEG3 long non-coding RNA prevents cell growth and metastasis of osteosarcoma

Zhang SZ¹, Cai L¹, Li B²

Department of Orthopedics, Zhongnan Hospital of Wuhan University, Wuhan, China. orthopedics@whu.edu.cn

ABSTRACT

OBJECTIVE: This study aimed to investigate the role of long non-coding RNA MEG3 (lncRNA MEG3) in osteosarcoma (OS) and further explore the underlying molecular mechanism.

MATERIALS AND METHODS: The expression profiles of MEG3 in OS cell lines and normal osteoblast cell line were detected by qRT-PCR. MEG3 was over-expressed in OS cell line by using LV-MEG3. MTT and colony-formation assays were applied for cell proliferation analysis. Cell migration assay was applied to investigate the cell migration ability. In addition, the expression levels of cell growth and metastasis related factors (Notch1, Hes1, TGF-β, N-cadherin and E-cadherin) were determined to illustrate the mechanisms.

RESULTS: We found that compared with normal osteoblast hFOB1.19 cell line, MEG3 was significantly down-regulated in MG63 and U2OS cell lines, particularly in MG-63 cells. MEG3 was significantly up-regulated in MG63 cells by LV-MEG3. Cell proliferation and migration ability were obviously repressed by MEG3 over-expression. In addition, MEG3 over-expression markedly inhibited Notch1, Hes1, TGF-β and N-cadherin expression, and the expression level of E-cadherin was improved.

CONCLUSIONS: These results indicated that MEG3 could prevent cell growth and metastasis of OS by repressing Notch and TGF-β signaling pathway, thus providing a potential therapeutic target for OS treatment (Tab. 1, Fig. 4, Ref. 30).

KEY WORDS: lncRNA MEG3, osteosarcoma, cell growth, metastasis.

Introduction

Osteosarcoma (OS), the most common primary malignant bone tumor in children and adolescents, is frequently derived from the long bones and characterized by immature bone or osteoid tissue production by malignant cells (1–3). OS has a very high degree of malignancy and a poor prognosis. Even with surgery combined with chemotherapy regimens, the main method for OS treatment, the patient’s annual survival rate is only 55–68 % (2, 4). The main reason for the poor prognosis of OS is the early occurrence of metastases. Patients with OS suffer from soft tissue swelling and severe pain which seriously affect the quality of patient’s life. Therefore, OS treatment has become an urgent problem for researchers to solve. Treatment at gene level has always been a hot spot in OS research, but its specific mechanism still needs further study, and finding effective therapeutic targets is the key to gene therapy.

Long non-coding RNAs (lncRNAs), a class of transcribed RNA of the genome without protein-coding potential, more than 200 nucleotides in length, play an important role in regulating gene expression by different mechanisms (5–7). Recent studies have demonstrated the expression profiles and functions of lncRNAs in various cancers (8). For example, lncRNA HOTAIR has been found to be increased in breast tumors and can promote metastasis via the regulation of Polycomb Repressive Complex 2 (9). High SPRY4-IT1 expression has been observed in renal cancer and down-regulation of SPRY4-IT1 reduces renal cancer cell proliferation, invasion and migration (10). EWSAT1 and SNHG12 were all found to be up-regulated in OS and act as tumor promoter (11, 12).

MEG3, a well studied lncRNA, is encoded by the MEG3 transcript of the DLK1/MEG3 locus on human chromosome, or Meg3 on mouse chromosome (13). A number of studies have demonstrated that lncRNA MEG3, a tumor suppressor gene, was down-regulated in various cancers and was associated with poor prognosis (14–18). A previous study indicated that the expression of lncRNA MEG3 was clearly lower in osteosarcoma tissues compared with adjacent non-tumor tissues (19). However, the exact role of lncRNA MEG3 in OS and the underlying molecular mechanism remains unclear. Thus, in the present study, we aim to investigate the role of lncRNA MEG3 in OS and further explore the underlying molecular mechanism.

Materials and methods

Cell culture

The human osteosarcoma (HOS) cell lines (MG63 and U2OS), and normal osteoblast hFOB1.19 cell lines were purchased from
American Type Culture Collection (ATCC). MG63 cells were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) (Gibco, America) containing 10% fetal bovine serum (FBS) (Gibco, America), 100 U penicillin and 100 mg/mL streptomycin (Invitrogen). The U2OS cells were cultured in RPMI 1640 medium. The hFOB1.19 cells were cultured in F12/DMEM (v/v: 1:1, HyClone) medium supplemented with 2.5 mM/L glutamine (without phenol red), 10% FBS and 0.3 mg/mL G418 (Sigma, St. Louis, MO, USA).

**Plasmids and cell transfection**

To over-express MEG3 in MG63 cells, lentivirus expressing whole MEG3 (LV-MEG3) and an empty vector (LV-GFP) were obtained from Genscript (Nanjing, China). The LV-MEG3 or LV-GFP was transfected into MG63 cells by using Lipo2000 (Invitrogen) according to the manufacturer’s instructions. After incubation for 48 h, cells were collected for following experiments. To verify the stable over-expression of MEG3 in MG63 cells, real-time PCR analysis was applied. Each experiment was repeated three times.

**MTT assay**

In the present study, cell viability was measured by performing MTT assay with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT, Sigma). In short, cells were seeded into 96-well plates (3×10^3 cells per well), after incubation for certain times, 20 μl MTT was added to each well and then incubated for another 4 h at 37 °C. Cell viability was assessed by detecting the absorbance at 490 nm using a microplate reader. All tests were performed in quadruplicate.

**Colony-formation assay**

For colony formation assay, the transfected cells (200 per well) were plated in a 6-well plate. The cells were cultured for 14 days under the standard culture conditions, and cell culture medium was replaced every 2–3 days. After fixing with methanol, stained by 0.5% crystal violet, formed colonies were photographed by Nikon camera (Nikon, Japan). All tests were performed at least three times.

**Tab. 1. Primer sequence for PCR.**

| Primer       | Sequence (5'-3') |
|--------------|-----------------|
| TGF-β-Forward| 5’GCTGTGAAAGCCCTTGAGTAGTG3’ |
| TGF-β-Reverse| 5’TTCCTGTTAAGCTGTTGCGATAA3’ |
| N-cadheren-Forward| 5’GACAATGGCCCTCAAGTTG3’ |
| N-cadheren-Reverse| 5’CCATTAAGCCCGTGTAGGTG3’ |
| Notch1-Forward| 5’GATCCGACTGTGACCTCG3’ |
| Notch1-Reverse| 5’GAATCCGGCCATCGCTTAC3’ |
| Hes1-Forward| 5’AGATAAGCTCGCGGCACTAG3’ |
| Hes1-Reverse| 5’ACCCTGCTGCTACCTCG3’ |
| MEG3-Forward| 5’CTGCCCATCTACACCTCAAG3’ |
| MEG3-Reverse| 5’CTTCCGCGTCTCGGTAGGGGCT3’ |
| GAPDH-Forward| 5’AGGCACATCGCTAGGACAC3’ |
| GAPDH-Reverse| 5’GCCCAATACGACCAATCC3’ |

**Cell migration assay**

To investigate the cell migration ability in different groups, cell migration assay was applied. Shortly, 48 h after cell transfection, cells were trypsinized and then re-seeded (1.0×10^5 cells per well) into serum-free DMEM in the upper chamber of a 24-well transwell (Corning, America). And DMEM supplemented with 20% FBS was added into the lower chambers. After incubation for 24 h, cells in the upper chamber were removed, and the cells in the lower chambers were stained by crystal violet. Tests were performed in triplicate.

**Quantitative real time PCR**

Total RNA from cells was isolated using the TRIzol reagent (Invitrogen, America) following the manufacturer’s instructions. Reverse transcription assay was carried out by using the cDNA Synthesis SuperMix (Trangene, Beijing, China) according to the manufacturer’s instructions. Real-time PCR was applied with ABI 7500 Real-time PCR instrument using the SYBR Green Master Mixture (Roche, America) reagent. GAPDH served as an internal control. The 2−ΔΔCt method was performed for the calculation.
of the relative expression of the genes. Primers used for PCR are listed in Table 1.

**Western blotting**

Cells were collected and lysed in RIPA buffer containing protease inhibitor cocktail. Protein samples were resolved by subjecting to 10% SDS-PAGE and then transferred to a nitrocellulose membrane. After blocked with 5% fat-free milk for 1 h at room temperature, the membranes were incubated with the primary antibodies (TGF-β/N-cadheren/ E-cadheren/Notch1/Hes1, 1:1000, CST, USA; β-actin, 1:2000, CST, USA) at 4°C overnight. Then, the membranes were incubated with a secondary antibody at room temperature for 2 h. The ECL detection system (Thermo Scientific, Waltham, MA, USA) was applied for the visualization of the bands.

**Statistical analysis**

Data were present as means ± SD. SPSS 16.0 software was carried out to calculate differences among groups by using one-way analysis of variance (ANOVA) or Student’s test. A value of p < 0.05 was considered significant.

**Results**

**MEG3 is down-regulated in OS cell line**

The expression level of lncRNA MEG3 in human osteosarcoma cell line MG-63, U2OS and osteoblast cell line hFOB1.19 was detected by qRT-PCR, and the results are shown in Figure 1A. Significant down-regulation of MEG3 was observed in OS cell lines compared with the normal osteoblast hFOB1.19 cell line. As MEG3 is less expressed in OS MG63 cells than in U2OS cells, MG63 cell line was selected for following experiments.

To investigate the role of MEG3 in OS cells, MEG3 was over-expressed in MG63 cells by transfection with LV-MEG3. As shown in Figure 1B, MEG3 was effectively up-regulated in MG63 cells by LV-MEG3.

**MEG3 over-expression inhibits MG63 cell proliferation**

48 h after cell transfection, MG63 cell proliferation was determined by performing MTT and colony-formation assays. We found that cell viability and cell clonality were obviously lower in LV-MEG3 MG63 cells than in LV-GFP and control MG63 cells (Fig. 2). The data indicated that MEG3 over-expression could prevent MG63 cell proliferation.

**MEG3 over-expression inhibits MG63 cell migration**

Cell migration ability of MG63 cells after cell transfection was detected by performing cell migration assay using a 24-well transwell. As shown in Figure 3, compared with the controls, the cell migration ability was markedly decreased in MG63 cells transfected with LV-MEG3. This data indicated that over-expression of MEG3 could inhibit MG63 cell migration.

**MEG3 over-expression affects the expression of tumor related factors**

To further explore the underlying molecular mechanisms of the functional role of MEG3 in OS cells, the expression levels of tumor related factors (TGF-β, N-cadheren, E-cadheren, Notch1 and Hes1) were determined by qRT-PCR and western blotting, respectively. As shown in Figure 4, both the mRNA and protein expression levels of TGF-β, N-cadheren, Notch1 and Hes1 were decreased when MEG3 was over-expressed. And E-cadheren was significantly up-regulated when MEG3 was over-expressed in MG63 cells.

**Discussion**

LncRNAs are involved in almost all cellular events, including cell proliferation, differentiation, apoptosis, etc. Accumulating evidence indicated that LncRNAs play critical roles in the progression of tumor. LncRNA MEG3, which is considered as a tumor suppressor gene, is well studied in a variety of cancers (20). MEG3 was down-regulated in cervical cancer, and is a potential marker for diagnosis and prognosis of patients with cervical cancer (21). Ectopic expression of MEG3 in nasopharyngeal carcinoma cells could inhibit cell proliferation, colony formation and induce cell cycle arrest (22). Guo et al found that MEG3 inhibits the proliferation of endometrial carcinoma cells via preventing Notch signaling pathway (23). Luo et al reported that MEG3 acts as a cancer inhibitor by inhibiting cell proliferation and inducing
Zhang ZH et al. MEG3 long non-coding RNA prevents cell growth and metastasis of osteosarcoma

635
Zhu et al suggested that MEG3 functions as a tumor suppressor in hepatoma cells through interacting with p53 protein (18). In addition to these studies, the role of MEG3 has been investigated in gallbladder cancer, NSCLC, neuroendocrine tumor, gastric cancer, thyroid carcinoma and so on (25, 14–17). However, to the best of our knowledge, the potential roles of MEG3 in OS remain largely unknown.

As lower expression of MEG3 has been verified in osteosarcoma tissues compared with adjacent non-tumor tissues in a previous study, in the present study, we first detected the expression level of MEG3 in human osteosarcoma cell lines (MG-63 and U2OS) and the normal osteoblast cell line (hFOB1.19). We found MEG3 is low expressed in the osteosarcoma cell line MG-63 and U2OS, especially in MG-63 cell line. We next investigated the effects of MEG3 on MG63 cell growth and migration by performing MTT, colony-formation assay and cellular migration transwell assay via MEG3 over-expression. The results of our study indicated that MEG3 over-expression significantly repressed the growth and migration ability of MG63 cells. Thus, we confirmed the tumor suppressor role of MEG3 in OS process which is consistent with previous research.

Notch signaling pathway has been demonstrated to be involved in the development of various cancers, and is a potential therapeutic target for cancer treatment (26, 27). TGF-β signaling pathway, one of the most important pathways in tumor cell EMT (an important factor of tumor cell metastasis), plays an important role in controlling tumor cell metastasis (28, 29). Previous studies have proved that MEG3 is related to Notch and TGF-β signaling pathways (23, 30). To further explore the mechanism of the effect of MEG3 on OS cell behavior, Notch and TGF-β signaling pathways were analyzed in our study. And we found that MEG3 over-expression inhibited the expression of Notch1, Hes1, TGF-β and N-cadheren, and enhanced E-cadheren expression.

Taken together, the data of the present study indicated that MEG3 prevents cell growth and metastasis of OS by inhibiting Notch and TGF-β signaling pathway. MEG3 may be used as a novel therapeutic target for OS treatment.

References
1. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 2009; 115: 1531–1543.
2. Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res 2009; 152: 3–13.
3. Geller D S, Gorlick R. Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol 2010; 8: 705–718.
4. Yang J, Zhang W. New molecular insights into osteosarcoma targeted therapy. Curr Opin Oncol 2013; 25: 398–406.

5. Serghiou S, Kyriakopoulou A, Ioannidis JP. Long noncoding RNAs as novel predictors of survival in human cancer: a systematic review and meta-analysis. Mol Cancer 2016; 15: 50.

6. Sullenger BA and Nair S. From the RNA world to the clinic. Science 2016; 352: 1417–1420.

7. Bartonicek N, Maag JL, Dinger ME. Long noncoding RNAs in cancer: mechanisms of action and technological advancements. Mol Cancer 2016; 15: 43.

8. Gibb EA, Brown CJ and Lam WL. The functional role of long non-coding RNA in human carcinomas. Mol Cancer 2011; 10: 38.

9. Gupta RA, Shah N, Wang KC et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010; 464: 1071–1076.

10. Zhang HM, Yang FQ, Yan Y et al. High expression of long non-coding RNA SPRY4-IT1 predicts poor prognosis of clear cell renal cell carcinoma. Int J Clin Exp Pathol 2014; 7: 5801–5809.

11. Sun L, Yang C, Xu J et al. Long Noncoding RNA EWSAT1 Promotes Osteosarcoma Cell Growth and Metastasis Through Suppression of MEG3 Expression. DNA Cell Biol 2016; 35: 812–818.

12. Ruan W, Wang P, Feng S et al. Long non-coding RNA small nucleolar RNA host gene 12 (SNHG12) promotes cell proliferation and migration by upregulating angiotatin gene expression in human osteosarcoma cells. Tumour Biol 2016; 37: 4065–4073.

13. Benetatos L, Vartholomatos G, Hatzimichael E. MEG3 imprinted gene contribution in tumorigenesis. Int J Cancer 2011; 129: 773–779.

14. Lu KHI, Li W, Liu XH et al. Long non-coding RNA MEG3 inhibits NSCLC cells proliferation and induces apoptosis by affecting p53 expression. BMC Cancer 2013; 13: 461.

15. Modali SD1, Parekh VI, Kebebew E et al. Epigenetic regulation of the lncRNA MEG3 and its target c-MET in pancreatic neuroendocrine tumors. Mol Endocrinol 2015; 29: 224–237.

16. Sun ML, Xia R, Jin F et al. Downregulated long noncoding RNA MEG3 is associated with poor prognosis and promotes cell proliferation in gastric cancer. Tumour Biol 2014; 35: 1065–1073.

17. Wang C, Yan G, Zhang Y et al. Long non-coding RNA MEG3 suppresses migration and invasion of thyroid carcinoma by targeting of Rac1. Neoplasma 2015; 62: 541–549.

18. Zhu J, Liu S, Ye F et al. Long noncoding RNA MEG3 interacts with p53 protein and regulates partial p53 target genes in hepatoma cells. PLoS One 2015; 10: e0139790.

19. Tian ZZ, Guo XJ, Zhao YM et al. Decreased expression of long non-coding RNA MEG3 acts as a potential predictor biomarker in progression and poor prognosis of osteosarcoma. Int J Clin Exp Pathol 2015; 8: 15138–15142.

20. Cui X, Jing, Long C et al. Long noncoding RNA MEG3, a potential novel biomarker to predict the clinical outcome of cancer patients: a meta-analysis. Oncotarget 2017.

21. Zhang J, Lin Z, Gao Y et al. Downregulation of long noncoding RNA MEG3 is associated with poor prognosis and promoter hypermethylation in cervical cancer. J Exp Clin Cancer Res 2017; 36: 5.

22. Chak WP, Lung RW, Tong JH et al. Downregulation of long non-coding RNA MEG3 in nasopharyngeal carcinoma. Mol Carcinog 2017; 56: 1041–1054.

23. Guo Q, Qian Z, Yan D et al. LncRNA-MEG3 inhibits cell proliferation of endometrial carcinoma by repressing Notch signaling. Biomed Pharmacother 2016; 82: 589–594.

24. Luo G, Wang M, Wu X et al. Long Non-Coding RNA MEG3 Inhibits Cell Proliferation and Induces Apoptosis in Prostate Cancer. Cell Physiol Biochem 2015; 37: 2209–2220.

25. Liu B, Shen ED, Liao MM et al. Expression and mechanisms of long non–coding RNA genes MEG3 and ANRIL in gallbladder cancer. Tumour Biol 2016; 37: 9875–9886.

26. Previs RA, Coleman RL, Harris AL et al. Molecular pathways: translational and therapeutic implications of the Notch signaling pathway in cancer. Clin Cancer Res 2015; 21: 955–961.

27. Takebe N, Nguyen D, Yang SX. Targeting notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol Ther 2014; 141: 140–149.

28. Zavadil J, Bottinger EP. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 2005; 24: 5764–5774.

29. Muraoka RS, Dumont N, Ritter CA et al. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 2002; 109: 1551–1559.

30. Mondal T, Subhash S, Vaid R et al. MEG3 long noncoding RNA regulates the TGF-β pathway genes through formation of RNA-DNA triplex structures. Nat Commun 2015; 6: 7743.

Received May 21, 2017. Accepted June 20, 2017.